李建勇
目前主要研究方向为淋巴增殖性疾病,主要开展慢性淋巴细胞白血病诊断、鉴别诊断、预后相关因素、发病机制及临床治疗研究。
个性化签名
- 姓名:李建勇
- 目前身份:
- 担任导师情况:
- 学位:
-
学术头衔:
博士生导师
- 职称:-
-
学科领域:
内科学
- 研究兴趣:目前主要研究方向为淋巴增殖性疾病,主要开展慢性淋巴细胞白血病诊断、鉴别诊断、预后相关因素、发病机制及临床治疗研究。
邓辉舫(DENG, Huifang),英籍华人,教授,博士生导师,教育部认证的高层次海外留学人才,1957年10月出生于湖南。分别于1981年及1985年在中国获得理学学士及理学硕士学位,于2000年在英国伦敦大学学院(UCL)获得理学博士学位。博士论文是2D液晶显示(LCD)系统关键技术研究(计算机模拟by有限元方法)。
由于他在理论凝聚态(理论物理)方面的出色研究,于1987年被破格提升为副教授,是年29岁。从1989年1月起,在英国学习,工作与生活。
从2001年1月到2004年9月,作为首席科学家及技术总监受聘于英国硅谷-剑桥一家高科技工程软件公司。以其深厚的数学功底及超常的算法分析能力使公司产品的功能及性能跃升到了一个至高的新层次,曾3次获得公司总裁颁发的杰出表现奖。
2004年9月,辞职受聘回国担任华南理工大学国家示范性软件学院院长。现为华南理工大学计算机科学与工程学院教授,博士生导师,先进计算、服务计算与科学计算团队负责人。
发表论文:
到目前为止共发表论文60多篇,其中近40篇在国外刊物上发表,7篇在国际一流刊物上发表(美国物理评论B (Phys. Rev. B)5篇,IEEE Trans 2篇),30篇被SCI,EI,ISTP索引,单篇最高引用次数为 16次。
科研项目:
在英国共主持大中型项目6项。其中包括欧共体项目:Predictive 3D micro-model simulation for Monitor LCDs。
回国后(2004.9)所进行的科研项目:1)用户状态管理子系统开发(企业) ;2)2006年广东省科技厅粤港关键领域重点突破招标立项:“无线射频识别(RFID)物流通关公共服务平台关键技术”(项目编号2006A15006003);3)2006年国家“863”先进制造技术领域RFID技术与应用重点项目:“面向物流应用的电子标签(RFID)服务系统研究”(课题编号:2006AA04A120);4)2007年教育部资助直属高校聘请外籍教师重点项目。
社会兼职:
英国剑桥旭日软件公司客座首席科学家;亚太地区ICT年度大奖赛特邀独立国际评委;2008年度《国家自然科学奖》特邀评审专家(英文组);2006年度863计划信息领域虚拟现实专题课题评议专家;2006年度和2008年度863计划信息技术领域智能感知与先进计算技术专题课题评议专家;IFITA2009 - 国际信息技术与应用论坛)审稿专家组成员;(美国) 国际制造技术与管理杂志(IJMTM)审稿人;广东省企业管理现代化成果评审委员会委员;粤港RFID产业联盟副主席;【大型文献馆藏传书】《当代湖南人-杰出人物篇》编纂委员会委员,并被录入该传书《杰出人物篇》;《中国科技论文在线》特聘评审专家。
个人主页:http://202.38.194.240:8180/CSWeb/showTeacher.html?id=48
-
主页访问
7020
-
关注数
0
-
成果阅读
422
-
成果数
10
李建勇, Si-Xuan Qian, Jian-Yong Li ∗, Tian Tian, Yun-Feng Shen, Yuan-Qiang Jiang, Hua Lu, Han-Xin Wu, Su-Jiang Zhang, Wei Xu
Leukemia Research 31(2007)1383-1388,-0001,():
-1年11月30日
The aim of this study was to evaluate the efficacy and toxicity of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (G-CSF) protocol in elderly patients with acute myeloid leukemia (AML). A total of 50 elderly patients including 8 aged over 70 years were enrolled. All patients were treated with CAG regimen including low-dose cytarabine (10 mg/m2 every 12 h, days 1-14), aclarubicin (10mg every day, days 1-8), and G-CSF (200 g/m2 every day, days 1-14) priming. The overall response rate was 72.0%, and 29 of 50 (58.0%) patients achieved complete remission, including 23 of 35 (65.8%) with previously untreated AML, 6 of 15 (40.0%) with refractory, relapsed or secondary AML, 4 of 8 (50.0%) aged over 70 years, 4 of 10 (40.0%) with unfavorable cytogenetic aberrations. The early death rate was 7.6%. The median overall survival was 14 months. Myelosuppression was mild to moderate, severe nonhematologic toxicity was not observed. Thus CAG priming regimen as the induction therapy is well tolerated and effective in elderly patients with AML.
Acute myeloid leukaemia, Cytarabine, Aclarubicin, Granulocyte colony-stimutating factor (, G-CSF), , Priming
-
31浏览
-
0点赞
-
0收藏
-
0分享
-
169下载
-
0评论
-
引用
【期刊论文】Review article MicroRNA gene expression in malignant lymphoproliferative disorders
李建勇, XU Wei and LI Jian-yong
Chin Med J 2007; 120(11): 996-999,-0001,():
-1年11月30日
Objective To review the recent studies about microRNAs and advances in malignant lymphoproliferative disorders. Data sources Published articles (2001-2006) about microRNAs and malignant lymphoproliferative disorders were selected using MEDLINE. Study selection After independent review by two observers, 43 of 421 originally identified articles were selected that specifically addressed the stated purpose. Results Two observers independently assessed studies using explicit methodological criteria for evaluating microRNAs in malignant lymphoproliferative disorders. Recent work has revealed a class of small noncoding RNA species, microRNAs, which affect various biological processes. MicroRNAs inhibit the expression of protein encoding genes at the posttranscriptional level in a variety of eukaryotic organisms. In this review, we focused on the biogenetic pathways of microRNAs (miR-15a, miR-16-1, miR-155, miR-17-92 cluster, miR-142) and discussed the implications for human malignant lymphoproliferative disorders. Conclusions microRNAs are involved in tumorigenesis and mediate gene regulation as a fundamental genetic program at the posttranscriptional level. Further study of microRNAs may lead to novel concepts in the diagnosis and treatment of malignant lymphoproliferative disorders.
microRNA, lymphoproliferative disorders
-
29浏览
-
0点赞
-
0收藏
-
0分享
-
110下载
-
0评论
-
引用
李建勇, Wei Xu, Jian-Yong Li ∗, Yu-Jie Wu, Hui Yu, Qiu-Dan Shen, Li Li, Lei Fan, Hong-Xia Qiu
Leukemia Research 32(2008)1071-1077,-0001,():
-1年11月30日
Chronic lymphocytic leukemia (CLL) is the most common adult form of leukemia in theWestern world, however, infrequent in the Eastern. It shows a remarkable heterogeneity, with some patients having an almost normal lifespan, others surviving only several years after diagnosis despite intensive therapy. To prospectively explore the prognostic significance of ATM and TP53 deletions in Chinese patients with CLL, interphase fluorescence in situ hybridization (FISH) and probes of LSI ATM and LSI p53 were used to detect ATM and TP53 deletions in 95 patients with CLL. ATM and TP53 deletions and their association with some other prognostic factors such as Binet stage, lymphocyte count in peripheral blood, serum lactate dehydrogenase (LDH), β2-microglobulin (β2-MG), CD38 and ZAP-70 expressions were analyzed. The Kaplan-Meier method was used to construct survival curves, and results were compared using the log-rank test. Univariate and multivariate Cox regression analyses were used to assess associations between survival time and potential risk factors. Out of the 95 patients with CLL, ATM gene deletion was found in 9 (9.5%) patients, TP53 gene deletion in 16 (16.8%) cases. There were no significant differences between ATM or TP53 deletion and clinical parameters of sex, age, Binet stage, lymphocyte count, LDH, β2-MG or ZAP-70 expression. However, the frequency of ATM and TP53 deletions were obviously higher in CD38-positive group than in CD38-negative group (P=0.001 and P=0.047, respectively). Among 41 patients received treatment with fludarabine and cyclophosphamide, there were nine patients with TP53 or ATM deletion, and no patient with these cytogenetic abnormalities achieved complete response (CR). Survival analysis showed that the patients with TP53 deletion had significantly shorter survival times than the patients without TP53 deletion. There was no evidence of important association between outcome and ATM gene deletion. Serum levels of LDH and β2-MG, CD38 expression, and TP53 deletion were the significant factors in determining overall survival (OS). TP53 deletion and CD38 expression were the variables strongly associated with OS by multivariate Cox regression analysis. It was showed that ATM or TP53 deletion is associated with high expression level of CD38 and TP53 deletion as a possible prognostic factor in Chinese patients with CLL.
Chronic lymphocytic leukemia, ATM gene, TP53 gene, Prognosis
-
54浏览
-
0点赞
-
0收藏
-
0分享
-
158下载
-
0评论
-
引用
李建勇, Wei Xu, Jian-Yong Li ∗, Si-Xuan Qian, Han-Xin Wu, Hua Lu, Li-Juan Chen, Su-Jiang Zhang, Rui-Lan Lu, Rui-Lan Sheng
Leukemia Research 32(2008)930-935,-0001,():
-1年11月30日
Modern intensive chemotherapy regimens have improved the prognosis for adult patients with acute lymphocytic leukemia (ALL). With these regimens, the complete response (CR) rates are approximately 75% and long-term disease-free survival (DFS) rates are about 20-35%. For patients with high-risk ALL, DFS rates are only 20% or less. Hyper-CVAD regimen is effective in ALL and aggressive non-Hodgkin lymphomas (NHL) with increased CR rates and DFS rates. Between June 2002 and October 2006, 53 consecutive adult patients with newly diagnosed adult ALL were treated with Hyper-CVAD regimen for six to eight cycles. The alternating courses were given every 3-4 weeks or earlier if count recovery occurred. CR rates of 73.6% were achieved in 39 patients, the estimated 2-year survival rate was 82.9% and the estimated 2-year event-free survival (EFS) rate was 87.3%. Side effects were as expected, mostly attributed to myelosuppression. Analysis of prognostic factors suggested that some previously well-established poor prognostic factors such as the degree of leukocytosis and central nervous system (CNS) or testicular involvement were less important with this dose-intensive regimen. However, patients with mediastinal disease had lower CR rates (P<0.05), with the presence of hepatomegaly and t(9;22) abnormalities had poor survival (P<0.05). Compared with other established adult ALL regimens, Hyper-CVAD regimen was associated with significantly better CR rates, overall survival and EFS rates. The long-term follow-up results of Hyper-CVAD were favorable.
Hyper-CVAD regimen, Acute lymphocytic leukemia, Treatment, Remission
-
63浏览
-
0点赞
-
0收藏
-
0分享
-
267下载
-
0评论
-
引用
李建勇, XU Wei, LI Jian-yong, WANG Li, YU Hui, ZHANG Su-jiang and SHENG Rui-lan
Chin Med J 2007; 120(22): 2056-2058,-0001,():
-1年11月30日
nonmyeloablative stem cell transplantation, hemoglobinuria,, paroxysmal
-
29浏览
-
0点赞
-
0收藏
-
0分享
-
106下载
-
0评论
-
引用
【期刊论文】CD38 as a prognostic factor in Chinese patients with chronic lymphocytic leukaemia
李建勇, Wei Xu, Jian-Yong Li ∗, Yu-Jie Wu, Hui Yu, Qiu-Dan Shen, Tian Tian, Li Li, Hong-Xia Qiu
Leukemia Research 33(2009)237-243,-0001,():
-1年11月30日
B-cell chronic lymphocytic leukemia (CLL) is the most common type of adult leukemia in the Western countries, however, infrequent in the Eastern. It shows a remarkable heterogeneity, with some patients having an almost normal lifespan, others surviving only several years after diagnosis despite intensive therapy. To explore the prognostic significance of CD38 expression in Chinese patients with CLL, multi-parameter flow cytometry was used to detect the expression of CD38 on CD5+CD19+ cells of 147 patients. CD38 expression and its association with some other prognostic factors such as Binet stage, lymphocyte count in peripheral blood, serum lactate dehydrogenase (LDH), 2-microglobulin (2-MG), ZAP-70 expression and cytogenetic abnormalities were analyzed. The Kaplan-Meier method was used to construct survival curves, and results were compared using the log-rank test. Univariate and multivariate Cox regression analyses were used to assess associations between survival time and potential risk factors. Out of the 147 CLL patients, positive expression of CD38 was found in 45 (30.6%) cases. CD38-positivity identified a subgroup of CLL patients with aggressive disease of Binet stage at the time of the test (P=0.036). Furthermore, the presence of higher serum LDH and 2-MG levels at diagnosis was strongly correlated with CD38-positive (P=0.016 and 0.025, respectively). Prognostically unfavorable cytogenetic abnormalities, including 17p13 and 11q22 deletions, were significantly more frequent in CD38-positive patients than in CD38-negative ones (P=0.047 and 0.001, respectively). Therewas no significant difference between CD38-positive and CD38-negative groups in molecular cytogenetic aberrations of del(6q23), del(13q14), 14q32 translocation, or trisomy 12. In addition, in CD38-positive patients, the percentage of leukemic cells expressing ZAP-70 protein was not significantly higher than in CD38-negative ones (P=0.120). CD38 expression was associated with poor outcome. Patients with positive expression of CD38 had significantly shorter overall survival (mean, 81 months) than patients without CD38 expression (mean, 179 months) (P=0.015). Univariate analysis showed that serum levels of LDH and 2-MG, del(17p13) and CD38 expression were the significant factors in determining overall survival (OS). Del(17p13) and CD38 expression were the variables strongly associated with OS by multivariate Cox regression analysis. It was showed that the patients with high level of CD38 expression had poorer outcome; CD38 was a good predictor of OS in Chinese patients with CLL.
Chronic lymphocytic leukemia, CD38 expression, Prognosis
-
34浏览
-
0点赞
-
0收藏
-
0分享
-
75下载
-
0评论
-
引用
【期刊论文】Clinical features and outcome of Chinese patients with monoclonal B-cell lymphocytosis
李建勇, Wei Xu, Jian-Yong Li ∗, Yu-JieWu, Xin Cao, Lei Fan, Chun Qiao, Qiong Liu, Lin Yao, Kou-Rong Miao
Leukemia Research 33(2009)1619-1622,-0001,():
-1年11月30日
B-cell chronic lymphocytic leukemia (CLL) is the most common type of adult leukemias in the Western countries, however, infrequent in the Eastern. A diagnosis of CLL requires a count of B-lymphocytes ≥5.0×109/L. Asymptomatic person with <5.0×109/L B-lymphocytes is defined as monoclonal B-cell lymphocytosis (MBL). To compare the clinical characteristics, prognostic factors, and outcome of Chinese patients with MBL and CLL, we present a study from our single centre of 20 patients with MBL and 136 patients with CLL. The factors included: age at diagnosis, gender, direct antiglobulin test (DAT), immunoglobulin heavy chain variable gene (IgHV) mutational status, ZAP-70 protein, CD38 expression level, and molecular cytogenetic aberrationswere analyzed in MBL and CLL subgroups. The Kaplan-Meier methodwas used to construct survival curves, and resultswere compared using the log-rank test. Patients in the MBL category were slightly older than in the CLL category. There was no significant difference of these clinical and biological characteristics between patients in MBL subgroup and early stage CLL (Binet A). The incidence of positive DAT was significantly increased in CLL patients at Binet B and C, compared with MBL (P=0.036). IgHV gene mutation in MBL is skewed, with more than 92.3% of subjects harbored mutated IgVH genes (P = 0.025). The proportion of MBL patients with a 13q14 deletion or trisomy 12 was similar to that of CLL patients. Moreover, markers associated with poor prognosis (deletion of 11q22 or 17p13) in these MBL populations were less than those in Binet B and C CLL patients (P=0.025). No statistically significant differences in ZAP-70 and CD38 status were observed between the MBL and CLL subgroups. During a median follow-up period of 45.5 months, MBL patients had a low probability of progression, with no patients transformed to aggressive non-Hodgkin’s lymphoma or dying of CLL-related causes. The overall survival of MBL was very similar to Binet A CLL, but longer than that of CLL patients at advanced stages (Binet B and C) (P=0.024). Our study demonstrated that a more indolent clinical course and superior clinical outcome for patients with MBL compared to CLL.
Monoclonal B-cell lymphocytosis Chronic lymphocytic leukemia Diagnosis Prognosis
-
55浏览
-
0点赞
-
0收藏
-
0分享
-
63下载
-
0评论
-
引用
李建勇, Su-Jiang Zhanga, ∗, Jing-Yi Shib, Jian-Yong Li a
Leukemia Research 33(2009)1141-1143,-0001,():
-1年11月30日
Chronic myeloid leukemia (CML) progression is characterized by occurrence of new cytogenetic and molecular abnormalities. In the previous study, we have shown the important role of GATA-2 L359 V mutation in CML progression. To further ascertain the truth of transcription factor GATA-2 in hematological malignancies, we expanded our study to GATA-2 full length by directly sequencing and applied MassARRAY assay intoGATA-2 L359 V mutation analysis. Finally, noGATA-2 L359 V mutationwas found in 270 acutemyeloid leukemia, 30myelodysplastic syndrome, 50 acute lymphoblastic leukemia, 12 chronic lymphocytic leukemia, 40 CML chronic phase and 286 BCR/ABL negative myeloproliferative disorders except CML blast crisis. A new variation of GATA-2 resulted in P250A change was identified, which was not found to have statistical difference between patients with hematological malignancies and healthy control. Hence,we concluded GATA-2 L359 V is exclusively associated with CML progression but not other hematological malignancies and P250A is a new single nucleotide polymorphism.
Chronic myeloid leukemia GATA-2 Mutation Single nucleotide polymorphism
-
58浏览
-
0点赞
-
0收藏
-
0分享
-
57下载
-
0评论
-
引用
【期刊论文】Trisomy 8 in two newly diagnosed Chinese patients with chronic lymphocytic leukemia
李建勇, Wei Xu, Xin Cao, Qiong Liu, Lei Fan, Kou-Rong Miao, Hai-Rong Qiu, Dan-Xia Zhu, Hong-Xia Qiu, Jian-Yong Li*
Cancer Genetics and Cytogenetics 192(2009)79-81,-0001,():
-1年11月30日
Chronic lymphocytic leukemia (CLL) is one of the most common lymphoid malignancies in Western countries, but is infrequent in Asian populations. To verify the incidence of trisomy 8 in Chinese patients with CLL, fluorescence in situ hybridization (FISH) was used in 140 CLL patiens after routine chromosome analysis. Only two patients (1.4%) were found with trisomy 8, and the number of trisomy 8 cells was 8 and 10%, respectively. No other aberrations by "panel" probe FISH were found in these two patients. The chromosome karyotypes of two patients were 47,XY,+8[2]/49,XY,+14,þ20,+21[2]/46,XY[16] and 47,XX,+8[2]/46,XX[18], respectively. Neither of the patients' present signs of myelodysplastic or myeloproliferative disorder appeared on the bone marrow aspirates and peripheral blood smear. Our study demonstrates that trisomy 8 is rare in CLL, and its role in prognosis of CLL remains unkuown.
-
35浏览
-
0点赞
-
0收藏
-
0分享
-
90下载
-
0评论
-
引用
李建勇, W. XU*, J.-Y. LI*, Q. LIU*, Y. ZHU*, J.-L. PAN†, H.-R. QIU*, Y.-Q. XUE†
Journal compilation 2008 Blackwell Publishing Ltd, Int. Jnl. Lab. Hem. 2010, 32, e86-e95,-0001,():
-1年11月30日
Complex chromosomal aberrations (CCA) can be detected in a substantial proportion of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), which are associated with very poor prognosis. Conventional cytogenetics (CC) cannot accurately define the specific alterations in CCA. Multiplex fluorescence in situ hybridization (M-FISH) allows the comprehensive identification of CCA. In this study, M-FISH was used in 16 patients with de novo MDS and 22 with AML with CCA detected by R-banding CC, and revealed 206 aberrations involved all 24 chromosomes, including 73 numerical chromosomal abnormalities and 133 structural abnormalities. The chromosomes most often involved were, by decreasing incidence, 5, 17, 8, 11, 7 and 21 in 57.9%, 55.3%, 44.7%, 36.8%, 34.2%and 34.2% of the cases, respectively. There were 98 unbalanced translocations, which were the most frequently observed aberrations in our study. Derivative chromosome 5 and 8 were implicated most often. The other derivatives were der(11), der(12), der(7), der(14), der(15) and der(17). Fourteen balanced translocations were detected in our series, and the most frequent reciprocal translocations was t(8;21). Fifty-five monosomies, 15 partial deletions, and 18 trisomies were found in all patients. The most frequently observed were -5/5q-, -17/17q-, -7, -18, -21, -19, and trisomy of chromosome 8 and 6. There were some abnormalities that have not been previously described, including two complex t(8;21) and seven unbalanced translocations. M-FISH could refine CCA, find or correct the missed or misidentified aberrations by CC analysis. Our findings confirmed that M-FISH was a powerful molecular cytogenetic tool to characterize complex karyotypes in MDS and AML.
Multiplex fluorescence in situ hybridization,, myelodysplastic syndromes,, acute myeloid leukemia,, complex chromosomal aberrations
-
34浏览
-
0点赞
-
0收藏
-
0分享
-
83下载
-
0评论
-
引用